Myomo, INC Form 4 insider transactions

Harry Kovelman, Chief Medical Officer of Myomo, Inc., received 32,500 shares of common stock on October 13, 2026.

Harry Kovelman, Chief Medical Officer of Myomo, Inc., sold 15,844 shares of common stock on September 11, 2026 for $1.27 per share.

David A Henry, Chief Financial Officer of Myomo, Inc., received 51,250 shares of common stock on October 13, 2026.

Paul R Gudonis, Chief Executive Officer and a Director of Myomo, Inc., received 71,250 shares of common stock on October 13, 2026.

David A Henry, Chief Financial Officer of Myomo, Inc., reported multiple transactions in common stock on October 9, 2026.

Paul R Gudonis, Chief Executive Officer and a Director of Myomo, Inc., received 8,363 shares of common stock on October 9, 2026.

Mary-Katherine Hale Mcclure, Chief Commericial Officer of Myomo, Inc., received 275,000 shares of common stock on October 12, 2026.

Harry Kovelman, Chief Medical Officer of Myomo, Inc., sold 17,500 shares of common stock on August 20, 2026 for $1.73 per share.

Harry Kovelman, Chief Medical Officer of Myomo, Inc., sold 17,250 shares of common stock on August 20, 2026 for $1.73 per share.

Harry Kovelman, Chief Medical Officer of Myomo, Inc., reported multiple transactions in common stock on August 7, 2026.

Micah Mitchell, Chief Commercial Officer of Myomo, Inc., reported multiple transactions in common stock on August 7, 2026.

Paul R Gudonis, Chief Executive Officer and a Director of Myomo, Inc., received 146,909 shares of common stock on August 7, 2026.

David A Henry, Chief Financial Officer of Myomo, Inc., reported multiple transactions in common stock on August 7, 2026.

David A Henry, Chief Financial Officer of Myomo, Inc., reported multiple transactions in common stock on July 10, 2026.

Paul R Gudonis, Chief Executive Officer and a Director of Myomo, Inc., received 10,454 shares of common stock on July 10, 2026.

Director Joseph M. Manko Jr. acquired 78,704 shares of MYOMO, INC. common stock on June 25, 2026, as part of a deferred stock award.

Thomas Aloysius Crowley Jr., a Director at Myomo, Inc., was granted 78,704 Restricted Stock Units (RSUs) on June 25, 2026, under the company's 2018 Stock Option and Incentive Plan.

Myomo, Inc. director Thomas F. Kirk was granted 78,704 Restricted Stock Units under the company's 2018 Stock Option and Incentive Plan.

Heather Getz, a Director at Myomo, Inc., was granted Restricted Stock Units (RSUs) representing 78,704 shares of common stock, with vesting scheduled to begin in September 2026.

William Febbo, a Director at Myomo Inc., has been granted 78,704 Restricted Stock Units (RSUs) under the company's 2018 Stock Option and Incentive Plan.

Myomo, Inc. director Milton Morris was granted Restricted Stock Units (RSUs) representing 78,704 shares of common stock under the company's 2018 Stock Option and Incentive Plan.

Chief Medical Officer Harry Kovelman sold 10,442 shares of Myomo, Inc. to cover tax obligations related to RSU vesting.

Chief Commercial Officer Micah Mitchell sold 9,061 shares of Myomo, Inc. to cover tax obligations related to restricted stock unit vesting.

Myomo, Inc. Chief Financial Officer David A. Henry reported the withholding of 10,969 shares to cover tax obligations related to RSU vesting.

Chief Commercial Officer Micah Mitchell sold 6,529 shares of Myomo, Inc. common stock to satisfy tax obligations related to RSU vesting.

Chief Medical Officer Harry Kovelman disposed of 7,635 shares of Myomo, Inc. to satisfy tax obligations related to RSU vesting.

Myomo, Inc. Chief Financial Officer, David A. Henry, acquired 10,050 shares of common stock on June 8, 2026, through a transaction to cover income taxes from vested restricted stock units.

Myomo, Inc. director Thomas F. Kirk has acquired 40,002 shares of common stock through open market purchases.

Micah Mitchell, Chief Commercial Officer of Myomo, Inc., reported the sale of 90,231 shares of common stock.

Myomo, Inc. director Thomas F. Kirk has acquired 25,000 shares of common stock in an open market transaction.